THE Therapeutic Goods Administration has approved Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.
The new OK marks the seventh indication for Opdivo which is also approved for other conditions including melanoma, lung cancer, kidney cancer and classic Hodgkin lymphoma.
BMS Australia and NZ gm Brent Pfeiffenberger said the new approval "reinforces the potential of immuno-oncology agents in treating hard-to-treat cancers".
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jul 17
